Decoding the Molecular Shift Behind Aggressive Brain Tumours

Meningiomas are the most common primary brain tumours in adults. While they often recur after treatment, most retain their original, lower-risk classification. However, a dangerous subset undergoes malignant transformation (MT), evolving into a more aggressive form. A new study has utilised sequential multi-omic analysis to uncover the drivers behind this shift.

By comparing patients whose tumours remained benign against those that turned malignant, researchers identified critical differences. The malignant tumours displayed a significantly higher burden of mutations and specific genetic losses, notably the deletion of cyclin-dependent kinase inhibitor 2A, a gene essential for regulating cell division. Additionally, these aggressive cases showed an upregulation of genes related to the cell cycle, such as Forkhead box M1.

Crucially, the study found that molecular warning signs appear early. Even before recurrence, tumours destined for malignancy exhibited distinct global DNA methylation patterns—chemical modifications that influence gene activity without changing the DNA sequence. These unique signatures suggest that aggressive biological pathways are established well before the tumour returns, underscoring the importance of molecular profiling in predicting patient outcomes.